Randomized trial · people
ARA-290 improved small fiber neuropathy symptoms in sarcoidosis
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This early, small human trial found ARA-290 well tolerated in sarcoidosis, with better neuropathy symptom scores than placebo but no edge on pain ratings.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 22
- Published
- 2012
- Journal
- Mol Med
What they tested
The team tested whether ARA-290 is safe and eases symptoms of small fiber neuropathy (damage to the body's thinnest nerve fibers, often causing pain) in people with sarcoidosis.
How the study was done
A randomized, double-blind, placebo-controlled pilot trial in 22 patients with sarcoidosis, neuropathy and a pain score of at least 5. The trial gave 2 mg of ARA-290 (12 patients) or a placebo, a dummy treatment (10 patients), into a vein three times a week for 4 weeks.

What they found
Clinical exams and lab tests turned up no safety problems. At week 4, scores on the small fiber neuropathy screening list (SFNSL, a symptom questionnaire) fell by 11.5 points in the ARA-290 group, compared with 2.9 points on placebo, a significant difference (p < 0.05). The ARA-290 group also showed significant shifts from its own starting point in the pain and physical functioning parts of the SF-36, a quality-of-life survey (changes of -23.4 and -14.6). Pain intensity and fatigue scores got better by the same amount in both groups, and depression scores did not move.
What it doesn’t show
This was a small, 4-week pilot trial, and the quality-of-life changes were measured against each patient's starting point rather than against placebo. Pain and fatigue improved no more with ARA-290 than with placebo.
The paper
Heij et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012.
The compound
More studies on ARA-290
- ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg armRandomized trial · people · 2017
- ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber lossRandomized trial · people · 2013
- ARA-290 eased nerve-injury pain for up to 20 weeks in ratsAnimal study · rats · 2014
- Every study on ARA-290
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.